Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04DTH
|
|||
| Drug Name |
Emapalumab
|
|||
| Synonyms |
emapalumab; Gamifant; emapalumab-lzsg; GTPL9295; Ni-0501; NI0501
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Primary haemophagocytic lymphohistiocytosis [ICD-11: 4A01.23; ICD-10: D76.1] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2/3 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN interferon gamma (IFNG) | Target Info | Inhibitor | [3], [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 761107. | |||
| REF 2 | ClinicalTrials.gov (NCT04324021) Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.. U.S. National Institutes of Health. | |||
| REF 3 | Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011. | |||
| REF 4 | Sobi to initiate a clinical study to evaluate whether anakinra and emapalumab may relieve complications associated with severe COVID-19 disease | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.